Sirion Biotech

 

SIRION Biotech was founded in Munich in 2006 with the idea of enabling novel cell models closer to reality than ever before. This required the assembly of an all-encompassing, novel viral vector platform. Both, designing de novo viral vectors and the subsequent creation of custom cell models will pave the way for superior compound development in the drug, cosmetics and food industries. SIRION’s technologies have been validated in over 300 single projects with more than 100 academic and industrial partners. As a result, primary cell immortalizations have become highly reliable, as have de novo viral vectors to be used in gene therapy and vaccine applications.

More info…

AAA